FINWIRES · TerminalLIVE
FINWIRES

奧本海默公司稱，在Auveality的標籤擴展決定出台之前，Axsome Therapeutics面臨著「極具吸引力的局面」。

By

-- 奧本海默公司週二在一份報告中指出，在FDA即將批准Auvelity用於治療阿茲海默症躁動症狀的適應症擴展之前，Axsome Therapeutics（AXSM）的股價可能面臨「極具吸引力的買入機會」。 奧本海默表示，FDA做出決定後，預測股價上漲空間為20%，機率為95%，下跌空間為35%。這項預測反映了該投資公司對該藥物約20億美元的銷售額預期，而優先審查資格也為其信心提供了支持。 該投資公司指出，Auvelity最初於2022年第三季獲準用於治療重度憂鬱症，並獲得了突破性療法認定，有望擴展適應症至阿茲海默症躁動症狀。 奧本海默公司表示，Auvelity 具有“顯著的商業優勢”，因為它“在安全性方面具有競爭力，這也使其能夠進入處方集並長期使用”，而其他同類阿茲海默症躁動藥物 Rexulti 則不具備這種優勢。 同時，報告指出，與 Cobenfy 等正在研發中的候選藥物相比，Auvelity 也具有很強的競爭優勢，後者「遠遠落後」。 奧本海默公司對 Axsome 的評級為“跑贏大盤”，目標價為 220 美元。

Price: $183.26, Change: $-5.43, Percent Change: -2.88%

Related Articles

Asia

Hong Kong Stocks Edge Lower as U.S.-Iran Talks Stall; CITIC Securities Gains on Profit Jump

Hong Kong stocks ended little changed Monday as U.S.-Iran talks stalled, heightening concerns over potential disruptions to energy flows.The Hang Seng Index fell 52.42 points to end marginally lower at 25,925.65, while the Hang Seng China Enterprises Index dropped 19.30 points to 8,756.32.U.S. President Donald Trump scrapped plans to send envoys to Islamabad for weekend talks, signaling a pause in diplomatic efforts.He said Sunday Iran could call if it wants to negotiate an end to the conflict, while insisting it must not possess nuclear weapons, after Tehran urged the removal of obstacles to a deal, including the U.S. blockade of its ports.Sentiment was partially supported after an Axios report said Iran may prioritize reopening the strait while postponing nuclear negotiations.Meanwhile, China's industrial profits accelerated in March, marking their fastest growth in six months.Profits rose 15.8% year on year, up from a 15.2% increase in the January-February period, according to data from the National Bureau of Statistics released Monday.In corporate news, CITIC Securities (HKG:6030, SHA:600030) closed nearly 2% higher after reporting a 55% growth in first-quarter profit.

$^HSI$HKG:6030$SHA:600030
Asia

WuXi AppTec's Q1 Profit Up 27%

WuXi AppTec (HKG:2359) booked 4.65 billion yuan in attributable profit for the first quarter of 2026, up 27% from 3.67 billion yuan a year earlier, according to a Hong Kong bourse filing Monday.Earnings per share were 1.58 yuan, compared with 1.28 yuan in the prior year.Revenue jumped 29% year on year to 12.44 billion yuan, figures showed.

$HKG:2359
Asia

Care Health Insurance CEO Steps Down

Religare Enterprises (NSE:RELIGARE, BOM:532915) said the managing director and chief executive officer of its subsidiary, Care Health Insurance, has stepped down from the role on April 25 upon completion of tenure, according to an Indian bourse filing on Sunday.Shares of the company rose nearly 2% in Monday's trade.

$BOM:532915$NSE:RELIGARE